SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.
about
Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedsideDual dopamine/serotonin releasers: potential treatment agents for stimulant addictionSleep and sleep homeostasis in mice lacking the 5-HT2c receptorDistribution of serotonin 5-HT2C receptors in the ventral tegmental areaSerotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorderReward-Induced Eating: Therapeutic Approaches to Addressing Food CravingsTPH2 in the ventral tegmental area of the male rat brainRegion-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptorsPharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway functionSerotonin, inhibition, and negative mood.Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Involvement of local serotonin-2A but not serotonin-1B receptors in the reinforcing effects of ethanol within the posterior ventral tegmental area of female Wistar rats.Impact of RNA editing on functions of the serotonin 2C receptor in vivo5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathwayNeurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference.The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeysSelective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration.Mirtazapine alters cue-associated methamphetamine seeking in ratsThe serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior.Dopamine and serotonin receptor binding and antipsychotic efficacy.The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues.Dissociable effects of 5-HT2C receptor antagonism and genetic inactivation on perseverance and learned non-reward in an egocentric spatial reversal task.Role of serotonin in cocaine effects in mice with reduced dopamine transporter function.Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stabilityHow Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study.Social Behavioral Deficits Coincide with the Onset of Seizure Susceptibility in Mice Lacking Serotonin Receptor 2c.Individual differences in the improvement of cocaine-induced place preference response by the 5-HT2C receptor antagonist SB242084 in ratsAttenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys by direct and indirect activation of 5-HT2C receptors.Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys.Genotype-Dependent Difference in 5-HT2C Receptor-Induced Hypolocomotion: Comparison with 5-HT2A Receptor Functional Activity.Improving temporal cognition by enhancing motivation.The effects of pharmacological modulation of the serotonin 2C receptor on goal-directed behavior in miceOlanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
P2860
Q24622161-764206C0-E8AE-4DF6-B339-B1B06DFEE86AQ24641896-F1C4EFE9-D495-407C-9185-3E4C041D2863Q24645006-8D35C4BA-B21B-4725-8289-1384ED210D65Q24682104-E85B7A68-2A88-4B0A-BCED-C9418F39AFDFQ27015917-D109578F-A2AC-47C3-A046-5A0F78584D2BQ28074195-3F095851-BC27-44FE-8EDF-C00BCCD62653Q28387425-E471256D-0B55-41F8-AFF0-879D136358C7Q28570213-F8CDAE67-D5A6-4DD7-A49C-2279B7334E44Q30493133-2963E1D7-CAD5-4153-BACE-986C096CC0FDQ30493995-99CFD7D6-2924-4AA8-B271-1DCEE208F3A3Q30499670-86DCA860-8944-4F6A-8D2B-257D098426D0Q33318080-132483D9-E651-4A4D-8EDF-9774488BB3BBQ33488312-418B5678-4BA8-431A-820B-FDDE9E586A0DQ33795138-6952F7DD-00C0-4DB4-AC56-9173EB07EB69Q33806232-56DDEF4E-C12A-4DBC-9052-2537F271BD47Q33936895-4F865CFC-2CD8-4A1F-8844-1165E095D9F5Q34012381-3279A689-C0E0-4777-A9FB-06870400F8ABQ34151743-AF13CCC3-1F52-481D-AE74-F1F26EC87970Q34206821-F6A5D258-76C6-4BD7-9736-E03D2E1347D8Q34280398-C51F2B0A-006D-4770-8B0E-D7199EDEFA99Q34310032-5A4B76F3-B263-44E6-AF68-0999AA9C6E14Q34462084-C807A434-F76A-4EC2-B185-8553C6534BDDQ34546304-AC97CA64-C388-4552-99D4-DA95C9F5D76FQ34572365-A343AA5F-347E-4278-8F06-84191A80B976Q34605995-6651C0DB-4EAE-4C85-A470-7CC00BE54B41Q34655896-4021B5C5-BB45-4483-A927-91EC1409AC27Q35035586-3095B8C6-55C8-4192-A576-63495E32A848Q35122959-B1860C0C-5BB7-4D4D-9EC0-2A094F3C8820Q35128324-E9581D0C-E943-417D-A0D6-C7346EF0CC0EQ35174992-F1188967-F672-46FB-B4F7-ABA548D0A021Q35755900-CB59822C-F80B-43B3-9231-569CE4DDD461Q35856962-C7AA7B74-5FB5-4255-92A6-73F8930153BFQ35889437-5F33DBF1-7580-46B4-ACB0-987DA5511A4BQ35913179-BAD0191D-4660-4E74-A74C-A21A3E1DEB0FQ36038551-CEACE75B-69A1-4E78-ACCE-1FAB787B830AQ36259005-0C0B485F-B80F-44AC-A51D-3B3A6332D38BQ36930837-4EA4EBED-82D3-4D62-880D-F28A57982488Q37252495-1617713E-E41D-4F6F-ABF8-BD5118693718Q37306537-8BE5E075-7DCE-4B98-B352-C67D9F2C81EEQ37737291-F9E42302-AC15-48FD-BB01-3870F32C4A86
P2860
SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@ast
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@en
type
label
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@ast
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@en
prefLabel
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@ast
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@en
P2093
P1433
P1476
SB 242084, a selective seroton ...... sion in the mesolimbic system.
@en
P2093
Di Giovanni G
Di Mascio M
Di Matteo V
Esposito E
P304
P356
10.1016/S0028-3908(99)00047-7
P577
1999-08-01T00:00:00Z